Adaptive Biotechnologies Announces Business Update Conference Call and Webcast Set for April 2, 2024

Unlocking the Potential of Adaptive Immunity: An Inside Look at Adaptive Biotechnologies Corporation’s Business Update

Adaptive Biotechnologies Corporation, a biotechnology company based in Seattle, is focused on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases. The company recently announced that they will be hosting a business update conference call and webcast on April 2, 2024, after the market closes. The event will begin at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time and will be accessible through the “Investors” section of their website at The webcast will also be archived for replay within 24 hours.

Adaptive Biotechnologies believes that the adaptive immune system can be a powerful tool for diagnosing and treating diseases, but its complexity has limited its full utilization. Their immune medicine platform aims to decode and leverage the genetics of the adaptive immune system with scale, precision, and speed. The company collaborates with biopharmaceutical companies, informs drug development, and develops clinical diagnostics in two main areas: Minimal Residual Disease (MRD) and Immune Medicine. Their products and clinical pipeline focus on diagnosing, monitoring, and treating diseases like cancer, autoimmune disorders, and infectious diseases, with the goal of creating personalized immune-driven clinical products for each patient.

For investors interested in Adaptive Biotechnologies, the company’s Vice President of Investor Relations, Karina Calzadilla, can be reached at 201-396-1687 or

Leave a Reply

China to oppose Biden’s electric vehicle agenda at the WTO Previous post China Files Complaint Against US over Electric Vehicle Subsidies in WTO Dispute: Uncertain Outcome as Appellate Body is Dysfunctional
Institute lowers forecasts as German economy faces challenges Next post Germany’s Economic Outlook for 2024: A Sluggish Growth, Political Uncertainty and High Inflation Rates